Search bioRxiv⌕ Search

Biology subjects

Bolz, S. N.

Publications and source records attributed to Bolz, S. N..

2 recordsLinked to original sources

Much ado about nothing: Modelling amino acid replacement with predicted protein structures

Substitution matrices like BLOSUM62 model the likelihood of replacement of amino acids in evolution. Substitution matrices are used in protein sequence alignment tasks. Since the introduction of BLOSUM62 over three decades ago, many matrices have been released. Yet, to date, no effort uses large amounts of 3D structures predicted by AlphaFold. Here, we define AFSM, the AlphaFold Substitution Matrix derived from over 20,000 predicted 3D structures following the BLOSUM methodology. We benchmark AFSM against BLOSUM62 and 16 other matrices on five tasks in multiple sequence alignment (MSA) and protein homology search. Our analysis surprisingly reveals that all matrices perform similarly. Only when there are few sequences in an MSA, then BLOSUM62 and AFSM perform better than using no matrix. This suggests that substitution matrices were most beneficial when there was little sequence data. We corroborate this argument by showing that embeddings, which are computed from billions of sequences, perform better than substitution matrices, when sequence data is sparse. Taken together, this suggests that structural data does not improve BLOSUM62. But increased sequence data makes extrapolation with substitution matrices obsolete. Nonetheless, BLOSUM62 continues to capture chemists intuition on amino acids by providing numerical values implicitly reflecting physicochemical properties, and it remains indispensable for direct comparison of two sequences.

bioinformatics↗

The structural basis of drugs targeting protein-protein interactions uncovered with the protein-ligand interaction profiler PLIP

Promiscuity of drugs and targets plays an important role in drug-target prediction, ranging from the explanation of side effects to their exploitation in drug repositioning. A specific form of promiscuity concerns drugs, which interfere with protein-protein interactions. With the rising importance of such drugs in drug discovery and with the large-scale availability of structural data, the question arises on the structural basis of this form of promiscuity and the commonalities of the underlying protein-ligand (PLI) and protein-protein interactions (PPI). To this end, we employ the protein-ligand interaction profiler, PLIP, to characterize the PLI and PPI of MDM2/p53, Bcl-2/BAX, XIAP/Casp9, CCR5/gp120, and BRD/H4. We show that the wealth of existing complexes in PDB, of predicted protein structures, and of molecular docking results gives deep insights into the design principles for drugs targeting protein interactions. Drugs targeting protein interaction interfaces are a promising avenue in drug discovery. Understanding drug and target promiscuity at a structural level will pave the way to deliver on this promise.

bioinformatics↗